| Name | Title | Contact Details |
|---|
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today`s cutting-edge research into tomorrow`s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children`s Hospital, Brigham and Women`s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center.
ADS is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced imaging, fluidics, chemistry and bioinformatics. Innovative, robust tools for spatial omics without compromise. Rebus Esper platform available now.
LabConnect is a global provider of clinical trial laboratory services, established in 2002 and based in Seattle, Washington. The company specializes in central laboratory solutions and functional service provider (FSP) support, partnering with pharmaceutical, biotechnology, and clinical research organizations. LabConnect has successfully managed over 1,900 clinical studies across 93 countries, emphasizing agility and innovation through a network of more than 30 laboratory locations worldwide. The company offers a range of services, including project management, a global testing network with over 10,000 validated tests, and comprehensive logistics and biorepository solutions. LabConnect also provides bioanalytical expertise and customized staffing for scientific project management. Its product offerings include customized lab kits for trial sites and integrated data management systems for real-time analytics. With a strong client portfolio that includes major pharmaceutical firms, LabConnect is positioned as a reliable partner for complex clinical trials.